AIFF Stock Overview
A medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Firefly Neuroscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.00 |
| 52 Week High | US$9.00 |
| 52 Week Low | US$2.74 |
| Beta | 0 |
| 11 Month Change | -16.67% |
| 3 Month Change | -40.51% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -64.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| AIFF | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -5.7% | 2.1% | 2.2% |
| 1Y | n/a | 8.2% | 31.6% |
Return vs Industry: Insufficient data to determine how AIFF performed against the US Healthcare Services industry.
Return vs Market: Insufficient data to determine how AIFF performed against the US Market.
Price Volatility
| AIFF volatility | |
|---|---|
| AIFF Average Weekly Movement | 21.8% |
| Healthcare Services Industry Average Movement | 9.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AIFF's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine AIFF's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 7 | Jon Olsen | fireflyneuro.com |
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners.
Firefly Neuroscience, Inc. Fundamentals Summary
| AIFF fundamental statistics | |
|---|---|
| Market cap | US$25.51m |
| Earnings (TTM) | -US$7.75m |
| Revenue (TTM) | US$74.00k |
344.7x
P/S Ratio-3.3x
P/E RatioIs AIFF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AIFF income statement (TTM) | |
|---|---|
| Revenue | US$74.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$74.00k |
| Other Expenses | US$7.83m |
| Earnings | -US$7.75m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 100.00% |
| Net Profit Margin | -10,475.68% |
| Debt/Equity Ratio | 0% |
How did AIFF perform over the long term?
See historical performance and comparison